Canada· CA-DIN-02530015
AURO-TOFACITINIB
A tofacitinib product containing tofacitinib (tofacitinib citrate), registered in Canada by AURO PHARMA INC. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Tofacitinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AF01 (tofacitinib), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Tofacitinib · ATC L04AF01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tofacitinib costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $1.99 in United States to $17.31 in Switzerland — a ×8.7 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Tofacitinib · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$17.31
- US United States$1.99 (acquisition cost)
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- TOFACITINIB (TOFACITINIB CITRATE)
- Manufacturer
- AURO PHARMA INC
- Country
- Canada (CA)
- ATC code
- L04AF01
- ATC class
- Tofacitinib
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
512 interactions on record for tofacitinib.
Graded by severity as the source publishes them — 333 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tofacitinib · interactions on record
512 records
- 333 severe
- 171 moderate
- 8 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tofacitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTofacitinibBreckenridge Pharmaceutical, Inc.
- United KingdomXeljanz 10mg tabletsPfizer Ltd
- CzechiaTOFACITINIB STADASTADA Arzneimittel AG, Bad Vilbel
- FinlandTofacitinib DevatisDevatis GmbH
- SwitzerlandTofacitinib Devatis 10 mg, FilmtablettenDevatis AG
- SwedenTofacitinib Devatis 10 mg Filmdragerad tablettDevatis GmbH
- NetherlandsTofacitinib Accord 10 mg filmomhulde tablettenAccord Healthcare B.V.
- BelgiumTofacitinib EG 10 mgEG
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Tofacitinib Devatis, Tofacitinib Stada
- Bulgaria · Tофацитиниб Devatis
- Denmark · Tofacitinib Accord, Tofacitinib Newbury
- Spain · Tofacitinib Stada
- Finland · Tofacitinib Devatis, Tofacitinib Stada
- France · Tofacitinib Stada
- United Kingdom (Northern Ireland) · Tofacitinib Amarox, Tofacitinib Brown & Burk Uk
- Croatia · Tofacitinib Accord, Tofacitinib Stada
- Iceland · Xeljanz
- Liechtenstein · Xeljanz
- Malta · Tofacitinib Stada
- Netherlands · Tofacitinib Devatis, Tofacitinib Stada
- Norway · Tofacitinib Accord, Tofacitinib Devatis
- Portugal · Tofacitinib Bluepharma
- Sweden · Tofacitinib Devatis, Tofacitinib Newbury
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/43f8adcd-a948-424e-afaa-e336c63e53c9 GET /v1/drugs/43f8adcd-a948-424e-afaa-e336c63e53c9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02530015",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L04AF01",
"schedule": [
"Prescription"
],
"drug_code": "101924",
"strengths": [
"10 MG"
],
"ahfs_class": null,
"substances": [
"TOFACITINIB (TOFACITINIB CITRATE)"
],
"product_categorization": null
}See everything about tofacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.